RxDoctor Payments Data

Lucyann Sciandra, DO

Infectious Disease · Wilkes Barre, PANPI 1326096884

Payments from drug & device makers

$2,076in general payments, 2019–2025

Across 32 payments — averaging $64.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$431
  • Phathom Pharmaceuticals, Inc.$251
  • Merck$233
  • Amarin Pharma, Inc.$175
  • Medtronic$171
  • AbbVie$135
  • plus $680 from 9 others

What the payments were for

  • Food & beverage$2,00697%
  • Education$703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,076 in reported general payments places this provider in the 75th percentile of 457 infectious disease providers in Pennsylvania.

See all infectious disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$144,668
Medicare patients
423
Services billed
1,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen40$160,118
BiktarvyBictegrav/Emtricit/Tenofov Ala39$151,591
Ampicillin Sodium17$4,332
Vancomycin Hcl28$3,262
Cephalexin101$2,371
Cefazolin Sodium33$2,042
Cefadroxil42$1,897
ValacyclovirValacyclovir Hcl26$1,177
CeftriaxoneCeftriaxone Sodium39$1,111
CefuroximeCefuroxime Axetil32$620
Cefdinir17$615
Doxycycline Hyclate25$456
Fluconazole17$438
Methenamine Hippurate12$277
Amoxicillin28$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy$431$311,70979 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 457 infectious disease providers in Pennsylvania.

Other infectious disease in Wilkes Barre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →